Dec 30, 2025 • Kalkine Media
SOMEWHAT-BULLISH
Vertex Pharmaceuticals (NASDAQ:VRTX) Nasdaq index Sustains Scientific Depth
Vertex Pharmaceuticals (NASDAQ:VRTX) continues to be a prominent player in the global biotechnology sector, with a focus on research-driven therapies for serious diseases such as cystic fibrosis. The company's ongoing scientific depth and activity keep it visible within the Nasdaq index. To access the full article, readers are prompted to log in, create an account, or fill out a form.
Dec 28, 2025 • Yahoo Finance
NEUTRAL
Zoetis (ZTS) Positioned Within Morgan Stanley’s 2026 Healthcare Playbook
Zoetis Inc. (NYSE: ZTS) is included in Morgan Stanley’s 2026 Healthcare Playbook and is among 15 dividend stocks with low payout ratios and strong upside potential. Morgan Stanley lowered its price target for ZTS to $160 from $175 but maintained an "Overweight" rating, citing attractive opportunities in healthcare technology and providers for 2026. The company recently received Health Canada approval for Portela™ (relfovetmab injection) for feline osteoarthritis pain, with commercial launches expected in Canada and the EU in 2026.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Yousif Capital Management LLC Boosts Stock Holdings in Elanco Animal Health Incorporated $ELAN
Yousif Capital Management LLC significantly increased its stake in Elanco Animal Health Incorporated by 1,333.7% in Q3 2025, now holding 168,133 shares valued at $3.39 million. This comes as Elanco exceeded Q3 earnings expectations and provided strong FY2025 guidance. Insider buying and institutional ownership of nearly 97.48% also highlight confidence in the company.
Dec 25, 2025 • ts2.tech
SOMEWHAT-BULLISH
Boston Scientific (BSX) Stock After Hours on Dec. 24, 2025: Key Moves, Today’s Fresh Analysis, and What to Watch Before Markets Reopen
Boston Scientific (NYSE: BSX) experienced a modest uptick in after-hours trading on Christmas Eve, closing at $96.13 in regular trading and $96.38 after hours. With markets closed on Christmas Day, investors are analyzing recent commentary focusing on the company's strong Endoscopy business and ongoing debate about its valuation, despite strong fundamental growth. Analysts maintain a "Buy" consensus with price targets significantly above the current trading price.
Dec 24, 2025 • FinancialContent
SOMEWHAT-BULLISH
Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025
In 2025, while the broader healthcare sector faced challenges, Zoetis Inc. (NYSE: ZTS) and Viatris Inc. (NASDAQ: VTRS) emerged as leaders due to their specialized focus on animal health and specialty/complex generics, respectively. Both companies demonstrated strong performance, with Viatris achieving a "beat and raise" quarter and Zoetis navigating regulatory scrutiny by highlighting its innovative pipeline in pet care. Their success underscores a shift towards specialized portfolios that are more resilient to policy changes and broader market volatility.
Dec 24, 2025 • FinancialContent
SOMEWHAT-BULLISH
Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025
Zoetis (NYSE: ZTS) and Viatris (NASDAQ: VTRS) are emerging as healthcare sector leaders in 2025, driven by their specialized portfolios in animal health and specialty/complex generics, respectively. Despite broader market headwinds, these companies have leveraged strategic innovation and strong earnings performances to outpace traditional pharmaceutical giants, attracting investors seeking durable growth. Their success highlights a shift towards niche markets in healthcare, insulated from policy changes affecting large pharma.